Open AccessEfficacy of adjuvant EGFR inhibitors and impact of clinical factors in resectedEGFR-mutated non-small-cell lung cancer: a meta-analysis
Author(s) -
Meichen Li,
Xue Hou,
Suxia Lin,
Lie Zheng,
Jieying Liang,
Jing Chen,
Na Wang,
Baishen Zhang,
Likun Chen
Publication year - 2022
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0934
Subject(s) - medicine , oncology , lung cancer , hazard ratio , epidermal growth factor receptor , chemotherapy , adjuvant therapy , adjuvant , cancer , confidence interval
Background: The role of adjuvant EGFR tyrosine kinase inhibitors (TKIs) in resected EGFR-mutated non-small-cell lung cancer (NSCLC) remains unclear. Materials & methods: We evaluated pooled hazard ratio and 95% CI for disease-free survival, overall survival and prespecified subgroups. Results: Seven prospective studies with 1288 patients were included in the meta-analysis. Adjuvant EGFR TKIs significantly improved disease-free survival in EGFR-mutated resected NSCLC (HR: 0.41; 95% CI: 0.24–0.70) and in all subgroups. However, the overall survival benefit was not significant (HR: 0.65; 95% CI: 0.36–1.17). The benefit of adjuvant TKIs may be associated with TKI regimens, treatment duration, pathological stage and EGFR mutation type. Conclusion: Adjuvant EGFR TKIs significantly improved disease-free survival and nonsignificantly improved overall survival in resected EGFR-mutated NSCLC.